CANADABIS CAPITAL INC (CANB.CA) Stock Fundamental Analysis
Canada - TSX-V:CANB - CA13530Q1046 - Common Stock
0.04 CAD
0 (0%)
CANB gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 31 industry peers in the Pharmaceuticals industry. While CANB is still in line with the averages on profitability rating, there are concerns on its financial health. CANB does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
CANB had negative earnings in the past year.
In the past year CANB has reported a negative cash flow from operations.
In multiple years CANB reported negative net income over the last 5 years.
CANB had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 0.28%, CANB is in the better half of the industry, outperforming 64.52% of the companies in the same industry.
CANB has a Return On Equity of 0.81%. This is in the better half of the industry: CANB outperforms 74.19% of its industry peers.
CANB's Return On Invested Capital of 2.07% is fine compared to the rest of the industry. CANB outperforms 67.74% of its industry peers.
The Average Return On Invested Capital over the past 3 years for CANB is significantly above the industry average of 7.71%.
The last Return On Invested Capital (2.07%) for CANB is well below the 3 year average (13.87%), which needs to be investigated, but indicates that CANB had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.28% | ||
| ROE | 0.81% | ||
| ROIC | 2.07% |
ROA(3y)8.58%
ROA(5y)-7.49%
ROE(3y)30.91%
ROE(5y)-44.74%
ROIC(3y)13.87%
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 0.41%, CANB is in the better half of the industry, outperforming 64.52% of the companies in the same industry.
CANB has a better Operating Margin (3.03%) than 70.97% of its industry peers.
CANB has a Gross Margin of 46.57%. This is in the better half of the industry: CANB outperforms 64.52% of its industry peers.
In the last couple of years the Gross Margin of CANB has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.03% | ||
| PM (TTM) | 0.41% | ||
| GM | 46.57% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.23%
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), CANB is creating value.
Compared to 1 year ago, CANB has about the same amount of shares outstanding.
Compared to 5 years ago, CANB has more shares outstanding
CANB has a better debt/assets ratio than last year.
2.2 Solvency
CANB has an Altman-Z score of 0.58. This is a bad value and indicates that CANB is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CANB (0.58) is better than 64.52% of its industry peers.
CANB has a Debt/Equity ratio of 1.07. This is a high value indicating a heavy dependency on external financing.
CANB's Debt to Equity ratio of 1.07 is on the low side compared to the rest of the industry. CANB is outperformed by 77.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.07 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.58 |
ROIC/WACC0.27
WACC7.62%
2.3 Liquidity
CANB has a Current Ratio of 1.58. This is a normal value and indicates that CANB is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of CANB (1.58) is worse than 61.29% of its industry peers.
A Quick Ratio of 0.33 indicates that CANB may have some problems paying its short term obligations.
CANB has a worse Quick ratio (0.33) than 90.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.58 | ||
| Quick Ratio | 0.33 |
3. Growth
3.1 Past
The earnings per share for CANB have decreased strongly by -97.47% in the last year.
Looking at the last year, CANB shows a decrease in Revenue. The Revenue has decreased by -8.85% in the last year.
CANB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.77% yearly.
EPS 1Y (TTM)-97.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-125%
Revenue 1Y (TTM)-8.85%
Revenue growth 3Y37.77%
Revenue growth 5YN/A
Sales Q2Q%-18.46%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
CANB's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. CANB is cheaper than 74.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 9.23 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
CANB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:CANB (10/30/2025, 7:00:00 PM)
0.04
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners53.52%
Ins Owner ChangeN/A
Market Cap5.52M
Revenue(TTM)17.16M
Net Income(TTM)69.90K
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.32 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.64 | ||
| P/tB | 0.64 | ||
| EV/EBITDA | 9.23 |
EPS(TTM)0
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.12
BVpS0.06
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.28% | ||
| ROE | 0.81% | ||
| ROCE | 3.3% | ||
| ROIC | 2.07% | ||
| ROICexc | 2.18% | ||
| ROICexgc | 2.18% | ||
| OM | 3.03% | ||
| PM (TTM) | 0.41% | ||
| GM | 46.57% | ||
| FCFM | N/A |
ROA(3y)8.58%
ROA(5y)-7.49%
ROE(3y)30.91%
ROE(5y)-44.74%
ROIC(3y)13.87%
ROIC(5y)N/A
ROICexc(3y)16.34%
ROICexc(5y)N/A
ROICexgc(3y)16.34%
ROICexgc(5y)N/A
ROCE(3y)24.27%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.23%
GM growth 5YN/A
F-Score2
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.07 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 6.6 | ||
| Cap/Depr | 19.78% | ||
| Cap/Sales | 1.03% | ||
| Interest Coverage | 1.29 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.58 | ||
| Quick Ratio | 0.33 | ||
| Altman-Z | 0.58 |
F-Score2
WACC7.62%
ROIC/WACC0.27
Cap/Depr(3y)74.66%
Cap/Depr(5y)403.75%
Cap/Sales(3y)2.7%
Cap/Sales(5y)24.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-97.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-125%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-8.85%
Revenue growth 3Y37.77%
Revenue growth 5YN/A
Sales Q2Q%-18.46%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-80.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-173.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-157.84%
OCF growth 3YN/A
OCF growth 5YN/A
CANADABIS CAPITAL INC / CANB.CA FAQ
Can you provide the ChartMill fundamental rating for CANADABIS CAPITAL INC?
ChartMill assigns a fundamental rating of 3 / 10 to CANB.CA.
What is the valuation status for CANB stock?
ChartMill assigns a valuation rating of 1 / 10 to CANADABIS CAPITAL INC (CANB.CA). This can be considered as Overvalued.
How profitable is CANADABIS CAPITAL INC (CANB.CA) stock?
CANADABIS CAPITAL INC (CANB.CA) has a profitability rating of 5 / 10.